ARID4B

Across TCGA pan-cancer cohorts, ARID4B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARID4B data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARID4B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARID4B expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where ARID4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	40	view →
PDAC	DFS	Median	All	0.867	0.666	<.001	27	view →
LSCC	DFS	Tertile	All	0.810	0.187	<.001	9	view →
HNSC	OS	Median	III,IV	0.787	0.912	.036	8	view →
CCRCC	DFS	Quartile	III,IV	0.734	1.000	.024	1	view →
GBM	OS	Tertile	All	0.489	0.255	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARID4B–LUAD (OS)

Open the LUAD breakdown →